Syncromune

Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to the development of an in situ platform therapy optimized for metastatic solid tumor cancers that aims to achieve high response rates with potentially improved survival. The company is currently developing SYNC-T, a novel and personalized in situ platform therapy that combines partial tumor oncolysis and a multi-target biologic drug. The SYNC-T combination approach is designed to target multiple mechanisms of cancer, promoting in situ immune activation while battling immunosuppression. The goal is to activate T cells, enabling the immune system to recognize and attack cancer throughout the body and defend...

Cancer vaccine,immunotherapy,metastatic solid tumors,mcrpc,multi-target biologic drug,combination cancer therapy,prostate cancer,breast cancer,lung cancer,bladder cancer,cervical cancer,renal cancer,head and neck cancer,intratumoral immunotherapy,and in situ cancer vaccine

Syncromune operates in the Biotechnology research industry.

Syncromune's revenue is 11m - 100m

Syncromune has 11 - 50 employees.